09:20 AM EDT, 05/21/2025 (MT Newswires) -- Silo Pharma ( SILO ) said Wednesday that it has signed a service agreement with medical technology firm Resyca for a drug-device study of its lead asset SPC-15, an intranasal prophylactic treatment for post-traumatic stress disorder, or PTSD.

Financial details were not disclosed.

Silo said the study is expected to provide the necessary device data and documentation for SPC-15's investigational new drug application, which the company plans to submit to the US Food and Drug Administration this year.

Silo is currently conducting two additional SPC-15 studies, it said.